Compare PENN & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PENN | TNDM |
|---|---|---|
| Founded | 1972 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 1996 | 2013 |
| Metric | PENN | TNDM |
|---|---|---|
| Price | $17.56 | $19.57 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 19 |
| Target Price | $20.83 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 4.0M | 1.4M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,362,900,000.00 | $1,014,736,000.00 |
| Revenue This Year | $6.85 | $8.11 |
| Revenue Next Year | $3.83 | $11.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 7.93 |
| 52 Week Low | $11.65 | $10.00 |
| 52 Week High | $20.61 | $29.65 |
| Indicator | PENN | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | 64.29 | 46.00 |
| Support Level | $16.60 | $17.90 |
| Resistance Level | $18.08 | $21.68 |
| Average True Range (ATR) | 0.81 | 1.19 |
| MACD | 0.19 | -0.07 |
| Stochastic Oscillator | 81.00 | 45.37 |
Penn Entertainment's origins date back to its 1972 racetrack opening in Pennsylvania. Today, Penn operates 43 properties across 20 states and 12 brands, including Hollywood Casino and Ameristar. Land-based casinos represented 85% of total sales in 2024; 15% was from the interactive segment, which includes sports, iGaming, and media revenue. The retail portfolio generates mid-30s EBITDAR margins and helps position the company to obtain licenses for the digital wagering markets. Additionally, Penn's media asset, theScore, provides access to sports betting/iGaming technology and clientele, helping it form a leading digital position.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.